BHP Acknowledges Decarbonisation Delay as Western Australian Premier Emphasises Miners Moral Responsibility Renegades Belmont Stakes Bid Could Shape Horse Racing Betting Market Pinterest Analyst Assessment Suggests Mixed Market Outlook Powell Vows No Shadow Chair Role but Potential Conflict with Warsh Looms Supermarkets Push Back as UK Government Rules Out Mandatory Price Caps on Milk Bread Eggs Major Tech Firms Establish 125 Million Semiconductor Research Hub at UCLA GAIA Q1 2026 Earnings Loss Narrowly Misses Estimates Shares Rise on Strategic Progress HCA Q1 2026 Earnings EPS Misses Estimates Amid Narrow Surprise and Flat Stock Reaction Novagold Resources NG Q1 2026 Earnings Narrower Loss Drives 74 Stock Gain SLM Q1 2026 Earnings EPS Surges Past Estimates on Strong Credit and Cost Control LTRN Q1 2026 Earnings NarrowerThanExpected Loss Highlights Cost Control as RD Pipeline Advances FWONK Q4 2025 Earnings Slight EPS Miss Amidst Steady Formula One Performance abrdn Global Dynamic Dividend Fund AGD Pulls Back Modestly After Recent Gains Scholar Rock SRRK Surges Over 6 Key Levels to Watch After the Jump AllianceBernstein Global High Income Fund AWF Edges Higher Faces Key Resistance at 1086 POET Technologies POET Declines 785 as Selling Pressure Builds Key Levels to Watch Urban One UONEK Holds Steady at 471 as Stock Consolidates Between Key Levels Kevin Warsh Poised for Internal Fed Clash Over Rate Cuts Amid Inflation and Yield Pressure UPWK Q1 2026 Earnings EPS Smashes Estimates Stock Reacts Positively FiEE Inc FIEE Edges Lower as Stock Tests Key Support Around 580 HTZ Q1 2026 Earnings NarrowerthanExpected Loss Lifts Shares Logitech LOGI Q1 2026 Earnings EPS Beats Estimates Amidst Cautious Market Response Hyliion Holdings Corp HYLN Q1 2026 Earnings Narrower Loss Fuels 42 Rally Healthpeak Properties DOC Q1 2026 Earnings Massive EPS Surprise of 515 Driven by Strong Operations TOST Q1 2026 Earnings Profitability Surprise Drives Modest Stock Uptick Nuvalent Inc NUVL Q1 2026 Earnings Slightly Wider Loss No Revenue Yet as PreClinical Pipeline Progresses MaxCyte Q1 2026 Earnings EPS Beat Highlights Operational Cost Discipline Amid Revenue Disclosure Gaps